Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA5A | P35218 | 5/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA6 | P23280 | 4/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013400 | 0.85 | PTGES2 (0.42) | SCN9APTGES2MEN1KMT2ACA2 | |
| SCHEMBL29418255 | 0.84 | MEN1 (0.56) | PTGES2MEN1KMT2ACA2CA1 | |
| SCHEMBL302570 | 0.84 | MEN1 (0.56) | PTGES2MEN1KMT2ACA2CA1 | |
| SCHEMBL4347732 | 0.84 | TSHR (0.47) | SCN9APTGES2MEN1KMT2ACA2 | |
| SCHEMBL8770175 | 0.82 | SCN9A (0.42) | SCN9APTGES2MEN1KMT2ACA2 | |
| Bromide SCHEMBL16335049 | 0.82 | MEN1 (0.55) | PTGES2MEN1KMT2ACA2CA1 | |
| Hydrochloric Acid SCHEMBL2640190 | 0.82 | MEN1 (0.55) | PTGES2MEN1KMT2ACA2CA1 | |
| SCHEMBL4761019 | 0.82 | SLC22A12 (0.46) | MEN1KMT2ACYP2C9SLC22A12ALDH1A1 | |
| SCHEMBL1080972 | 0.82 | CA2 (0.61) | MEN1KMT2ACA2CA1CA5A | |
| SCHEMBL18240869 | 0.81 | MEN1 (0.46) | MEN1KMT2ASLC22A12ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SCN9A 4763/4885PTGES2 161/4885MEN1 4160/4885 |
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | SCN9A 4784/4885PTGES2 67/4885MEN1 1999/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SCN9A 4763/4885PTGES2 161/4885MEN1 4160/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | SCN9A 4764/4885PTGES2 43/4885MEN1 2864/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | SCN9A 4763/4885PTGES2 161/4885MEN1 4160/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | SCN9A 4764/4885PTGES2 43/4885MEN1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.